Immunogenicity Expertise EpiVax has over 25 years of immunogenicity experience and offers risk-based, fit-for-purpose assessment that integrates computational analyses, in vitro assays, and expert consulting to de-risk pipelines, which can be positioned to potential clients seeking comprehensive immunogenicity services.

Expanded Capabilities Recent investments in AI-enabled ISPRI enhancements, AI-enhanced immunogenicity prediction models, ADA 2.2 updates, and ongoing expansion of laboratory facilities indicate a broader, more capable platform that can attract partnerships requiring advanced analytics and scalable testing.

Strategic Growth SV Health Investors’ acquisition and the Rhode Island facility expansion signal strong growth momentum and stability, creating opportunities to pitch long-term collaboration, co-development, and expanded service scopes as the company scales.

Leadership & Vision New CSO appointment and continued senior scientific leadership emphasize a commitment to expanding computational tools, diversified cell-based assays, and enhanced consulting, which can be leveraged to engage decision-makers seeking innovative immunogenicity solutions.

Market Positioning With a mid-size biotech focus and a track record supporting startups to global leaders, EpiVax can be framed as a flexible, risk-mitigating partner for early-stage to late-stage programs, enabling conversations around pipeline safety, regulatory strategy support, and efficiency gains.